Elizabeth Coker

Citado por

	Total	Desde 2019
Citas	760	648
Índice h	10	10
Índice i10	11	11

220

110

165

201420152016201720182019202020212022202320247 23 24 29 24 35 43 96 154 214 101

Acceso público

Ver todo

16 artículos

0 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Bissan Al-LazikaniProfessor, Genomic Medicine; Director Therapeutics Data ScienceDirección de correo verificada de mdanderson.org
Albert A. AntolinICR Fellow / Junior Team Leader, The Institute of Cancer Research, UKDirección de correo verificada de icr.ac.uk
Mathew GarnettWellcome Sanger InstituteDirección de correo verificada de sanger.ac.uk
Paul WorkmanChief Executive & President, Institute of Cancer Research, LondonDirección de correo verificada de icr.ac.uk
Krishna C BulusuAstraZenecaDirección de correo verificada de astrazeneca.com
Christos C. KannasMachine Learning/Cheminformatics Expert, AstraZeneca AB, ORCID: 0000-0001-7312-8193Dirección de correo verificada de astrazeneca.com
Johann de BonoInstitute of Cancer ResearchDirección de correo verificada de icr.ac.uk
James CampbellLead Bioinformatician, Head of CRUK Bioinformatics Facility, Institute of Cancer ResearchDirección de correo verificada de icr.ac.uk
Sebastian PölsterlComputational Pathology, Oncology R&D, AstraZenecaDirección de correo verificada de poelsterl.net
Ben KinnersleyUCL Cancer Institute - Senior Computational BiologistDirección de correo verificada de ucl.ac.uk
Amit SudDana-Farber Cancer Institute and University of OxfordDirección de correo verificada de dfci.harvard.edu
David BasantaProfessor of Mathematical Oncology at the Moffitt Cancer CenterDirección de correo verificada de cancerevo.org
Andrew DhawanAssociate Staff Neuro-Oncologist and Physician-Scientist, Cleveland ClinicDirección de correo verificada de ccf.org
Anguraj SadanandamGroup Leader, Institute of Cancer Research (ICR), LondonDirección de correo verificada de icr.ac.uk
Francesco IorioHuman TechnopoleDirección de correo verificada de fht.org
Paul H HuangTeam Leader, Molecular & Systems Oncology, Institute of Cancer Research, London, UKDirección de correo verificada de icr.ac.uk
Emanuel GonçalvesINESC-ID & IST - Universidade de LisboaDirección de correo verificada de tecnico.ulisboa.pt
Daniel J. VisNetherlands Cancer Institute, Amsterdam, The NetherlandsDirección de correo verificada de nki.nl

Seguir

Elizabeth Coker

AstraZeneca, Cambridge

No hay ninguna dirección de correo electrónico verificada.

Computational biology drug discovery drug combinations network biology cancer biology


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Effective drug combinations in breast, colon and pancreatic cancer cells P Jaaks, EA Coker, DJ Vis, O Edwards, EF Carpenter, SM Leto, L Dwane, ... Nature 603 (7899), 166-173, 2022	190	2022
canSAR: an updated cancer research and drug discovery knowledgebase JE Tym, C Mitsopoulos, EA Coker, P Razaz, AC Schierz, AA Antolin, ... Nucleic acids research 44 (D1), D938-D943, 2016	105	2016
canSAR: updated cancer research and drug discovery knowledgebase KC Bulusu, JE Tym, EA Coker, AC Schierz, B Al-Lazikani Nucleic acids research 42 (D1), D1040-D1047, 2014	100	2014
canSAR: update to the cancer translational research and drug discovery knowledgebase C Mitsopoulos, P Di Micco, EV Fernandez, D Dolciami, E Holt, IL Mica, ... Nucleic acids research 49 (D1), D1074-D1082, 2021	78	2021
Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens E Gonçalves, A Segura‐Cabrera, C Pacini, G Picco, FM Behan, P Jaaks, ... Molecular Systems Biology 16 (7), e9405, 2020	71	2020
canSAR: update to the cancer translational research and drug discovery knowledgebase EA Coker, C Mitsopoulos, JE Tym, A Komianou, C Kannas, P Di Micco, ... Nucleic acids research 47 (D1), D917-D922, 2019	58	2019
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models C Winkler, J Armenia, GN Jones, L Tobalina, MJ Sale, T Petreus, T Baird, ... British Journal of Cancer 124 (5), 951-962, 2021	48	2021
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x_L, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia SB Balachander, SW Criscione, KF Byth, J Cidado, A Adam, P Lewis, ... Clinical Cancer Research 26 (24), 6535-6549, 2020	48	2020
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers A Stewart, EA Coker, S Pölsterl, A Georgiou, AR Minchom, S Carreira, ... Molecular cancer therapeutics 18 (8), 1396-1404, 2019	16	2019
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor … V Flemington, EJ Davies, D Robinson, LC Sandin, O Delpuech, P Zhang, ... Molecular cancer therapeutics 20 (2), 238-249, 2021	15	2021
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors S Dunn, C Eberlein, J Yu, A Gris-Oliver, SH Ong, U Yelland, N Cureton, ... Oncogene 41 (46), 5046-5060, 2022	10	2022
Individualized prediction of drug response and rational combination therapy in NSCLC using artificial intelligence–enabled studies of acute phosphoproteomic changes EA Coker, A Stewart, B Ozer, A Minchom, L Pickard, R Ruddle, S Carreira, ... Molecular cancer therapeutics 21 (6), 1020-1029, 2022	6	2022
SiGNet: A signaling network data simulator to enable signaling network inference EA Coker, C Mitsopoulos, P Workman, B Al-Lazikani Plos one 12 (5), e0177701, 2017	6	2017
Leveraging human genetics to guide cancer drug development B Kinnersley, A Sud, EA Coker, JE Tym, P Di Micco, B Al-Lazikani, ... JCO Clinical Cancer Informatics 2, 1-11, 2018	4	2018
Simulated ablation for detection of cells impacting paracrine signalling in histology analysis JP Taylor–King, E Baratchart, A Dhawan, EA Coker, IH Rye, H Russnes, ... Mathematical Medicine and Biology: a Journal of the IMA 36 (1), 93-112, 2019	2	2019
Abstract B096: canSAR, a cancer research and drug discovery knowledgebase EA Coker, P Di Micco, JE Tym, C Mitsopoulos, A Komianou, AA Antolin, ... Molecular Cancer Therapeutics 17 (1_Supplement), B096-B096, 2018	2	2018
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations AC Bashi, EA Coker, KC Bulusu, P Jaaks, C Crafter, H Lightfoot, M Milo, ... Cancer Discovery 14 (5), 846-865, 2024	1	2024
Large scale pan cancer drug combination screening to identify effective and actionable combinations and biomarker hypothesis A Bashi, EA Coker, K Bulusu, M Milo, C Crafter, J Lynch, D Jenkins, ... Cancer Research 83 (7_Supplement), 5321-5321, 2023		2023
Activity and tolerability of combination of venetoclax with the Aurora kinase B Inhibitor AZD2811 in preclinical diffuse large B-cell lymphoma models A Cheraghchi-Bashi, B Willis, K Mongeon, J Gordon, K Bulusu, E Coker, ... Cancer Research 82 (12_Supplement), 6303-6303, 2022		2022
Combining selumetinib with BH3 mimetics enhances activity in MAPK-activated acute myeloid leukemia CL Andersen, A Cheraghchi-Bashi, P Jaaks, EA Coker, K Burke, J Cidado, ... Cancer Research 82 (12_Supplement), 4024-4024, 2022		2022

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores